Mechanistically, inhibition of the PI3K pathway increased AR signaling in PTEN‐deficient prostate cancer in part via relief of negative feedback to HER kinases; conversely, AR antagonism relieves feedback inhibition of AKT by reducing FKBP5‐mediated stability of the phosphatase PHLPP. This evidence concerns the gene PTEN and prostate cancer.